This topic supplements the topic "Morphea - localised scleroderma" .
- UVA1 phototherapy is currently recommended as the first line treatment for morphea and can even treat long established morphea.
- It is very common for morphea to occur along with linear scleroderma, since they are both forms of localised scleroderma.
- It is possible to have non skin manifestations with localised scleroderma but it's important to note that localised scleroderma does not become systemic scleroderma, they are two entirely separate diseases although it it possible to have both.
- "A 2003 large multinational study found that 25% of people with localised scleroderma had at least one other manifestation, such as osteoarticular, neurological (epilepsy, headache, peripheral neuropathy), ocular, vascular, gastrointestinal (heartburn) respiratory, cardiac or renal. Less that 4% of people with morphea had more than two non skin manifestations and none of the people in the study went on to develop systemic scleroderma."
- Approximately 2% of people with morphea have anti-centromere (ACA) antibodies, which means that they may be at risk of also developing systemic scleroderma. People with morphea should therefore have annual physical examinations to check for any additional symptoms and also be tested for the anticentromere antibodies (ACA).